Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer

This publication has 105 references indexed in Scilit:

• Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase
  PLOS ONE, 2013
• Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
  New England Journal of Medicine, 2012
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  Annals of Oncology, 2011
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
  New England Journal of Medicine, 2010
• Proteasome inhibition represses ERα gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer
  Oncogene, 2009
• Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
  Breast Cancer Research and Treatment, 2009
• Biological determinants of endocrine resistance in breast cancer
  Nature Reviews Cancer, 2009
• Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
  Journal of Clinical Oncology, 2009
• A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
  Proceedings of the National Academy of Sciences, 2006
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogene
  Science, 1987